Teva reports discontinuation of its generic Saxenda five-pen carton
Teva's generic version of the daily liraglutide injection Saxenda is listed as discontinued in one FDA record while another shows a 2027 end date, leaving patients and pharmacists with an unclear timeline.
Teva Pharmaceuticals has told the FDA it is discontinuing its generic version of Saxenda, the once-daily liraglutide injection used for weight management. The posting in the FDA's drug shortage database is dated May 14, 2026 and covers the five-pen carton, NDC 0480-7250-46, a 6 mg/mL liraglutide injection [1]. The reason listed for the entry is "Discontinuation of the manufacture of the drug," and the page for liraglutide injection now carries the overall status "Discontinuation" [1].
The FDA's records do not agree on when the product ends. The agency's National Drug Code directory lists a marketing end date of Sept. 30, 2027 for the same package, NDC 0480-7250-46, with a marketing start date of Aug. 28, 2025 [2]. Teva's product is approved under ANDA214568 [2]. FDA has not explained the gap between a May 2026 discontinuation posting and a September 2027 marketing end date, and the notices do not say why Teva is stopping production or when its current supply will run out [1][2].
The brand version is also winding down. Novo Nordisk posted a notice dated Aug. 25, 2026 stating that Saxenda 6 mg/mL, NDC 0169-2800-15, "will be available until discontinuation in January 2027" [1].
Liraglutide is a different molecule from semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus, and from tirzepatide, the ingredient in Mounjaro and Zepbound. Saxenda is a liraglutide product approved for weight management, while Novo Nordisk's Victoza is a liraglutide product approved for type 2 diabetes [2]. Teva's discontinued carton is a generic version of the Saxenda five-pen carton [1][2].
Other liraglutide products remain listed in FDA's NDC directory, including Meitheal Pharmaceuticals' generic liraglutide two-pen and three-pen cartons, first marketed April 2, 2025 [2], and Novo Nordisk's Victoza and Saxenda listings [2]. A directory entry is not a guarantee that a product is in stock. A search of the NDC directory for liraglutide returns 62 records, many of them bulk ingredient listings rather than finished medicine [2].
Why it matters for patients
Liraglutide is one of several GLP-1 medicines on the US market, and the FDA records now point to the brand and at least one generic version of the Saxenda carton leaving it. Because the discontinuation notice and the marketing end date do not match, pharmacists checking the same FDA databases may see different answers depending on which record they open [1][2]. The five-pen carton is identified by NDC 0480-7250-46, and that number appears on the packaging, so the carton itself is the clearest way to tell whether a specific product is the one affected [2].
A discontinuation posting is not a safety warning. FDA's page for liraglutide injection lists a discontinuation status rather than a recall, and the records do not describe any problem with the medicine itself [1]. What the notices do not establish is how quickly supply shrinks, whether other manufacturers will absorb the demand, or how insurers and pharmacy chains will handle the change. None of that has been reported in these FDA records [1][2].
What happens next
Novo Nordisk's notice says brand Saxenda will stay available until its discontinuation in January 2027 [1]. Teva's NDC directory entry carries a marketing end date of Sept. 30, 2027 [2]. FDA has not said when Teva's supply is expected to end, and no further filings on the Teva carton have been disclosed beyond the May 14, 2026 posting [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.